Systemic lupus erythematosus

Medicine

Volumn 34, Issue 11, 2006, Pages 445-452

  Li, Charles K ^a,b   Isenberg, David A ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

B cell depletion; dsDNA autoantibody; mycophenolate; systemic lupus erythematosus; UV light

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; COMPLEMENT; COMPLEMENT COMPONENT C1Q; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DAPSONE; DNA ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; HLA ANTIGEN; HYDRALAZINE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN RECEPTOR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSOME AUTOANTIBODY; ORAL CONTRACEPTIVE AGENT; PENICILLAMINE; PRASTERONE; PREDNISONE; PROCAINAMIDE; RIBONUCLEOPROTEIN ANTIBODY; RITUXIMAB; RO ANTIBODY; SINGLE STRANDED DNA; UNINDEXED DRUG;

AFRICAN CARIBBEAN; ANTIBODY DETECTION; ARTHROPATHY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BEHAVIOR MODIFICATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; ENVIRONMENTAL FACTOR; EYE DISEASE; GENETIC ANALYSIS; GENETICS; HEART DISEASE; HEMODIALYSIS; HEMOLYSIS; HORMONE DETERMINATION; HUMAN; INDIVIDUALIZATION; INFECTION; INFERTILITY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIFESTYLE; LUNG DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS LIKE SYNDROME; LYMPHOCYTE DEPLETION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; NEURITIS; NONHUMAN; PATHOGENESIS; PATIENT CARE; PERITONEAL DIALYSIS; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATIC DISEASE; SEX RATIO; SKIN DISEASE; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; ULTRAVIOLET RADIATION;

EID: 33845372231     PISSN: 13573039     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.mpmed.2006.09.002     Document Type: Review

References (9)

1. Sanchez-Guerrero J., Karlson E.W., Liang M.H., Hunter D.J., Speizer F.E., and Colditz G.A. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 40 (1997) 804-808
2. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
3. Salmon M., and Gordon C. The role of apoptosis in systemic lupus erythematosus. Rheumatology 38 (1999) 1177-1183
4. Karrar A., Sequeira W., and Block J.A. Coronary artery disease in systemic lupus erythematosus: a critical review of the epidemiological evidence. Semin Arthritis Rheum 30 (2001) 436-443
5. Sultan S.M., Ioannou Y., and Isenberg D.A. A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology 38 (1999) 917-932
6. Weening J.J., D'Agati V.D., Schwartz M.M., et al. Classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15 (2004) 241-250
7. Howie A.J., Turhan H., and Adu D. Powerful morphometric indicator of prognosis in lupus nephritis. Q J Med 6 (2003) 411-420
8. Isenberg D., and Ramsey-Goldman R. Assessing patients with lupus. Toward a drug responder index. Rheumatology 38 (1999) 1045-1049
9. Leandro M.J., Cambridge G., Edwards J.C., Ehrenstein M.R., and Isenberg D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 44 (2005) 1542-1545